Phaseline

Companies › Helios Cardio

Helios Cardio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Amiodarone-Infused CardiaMend patches
Topical amiodarone delivery to epicardial atrial surface
Ion channelsPhase 1Atrial Fibrillation, Postoperative–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06730828Amiodarone-Infused CardiaMend patchesPhase 1Atrial Fibrillation, PostoperativeCardiovascularNov 2025

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.